The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Ozempic, the popular diabetes drug widely used for weight loss, was among the 15 prescription drugs selected for Medicare price negotiations announced by President Joe Biden's administration on Friday (January 17),

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.